BCL-2: A New Therapeutic Target in Estrogen Receptor-Positive Breast Cancer?

Prosurvival protein BCL-2 is overexpressed in estrogen receptor positive (ER+) breast cancer. In this issue of Cancer Cell, Vaillant and colleagues demonstrate that targeting BCL-2 with BH3 mimetics improves the response of xenografts from primary ER+ breast tumors to endocrine therapy and reduces tamoxifen-induced endometrial hyperplasia, a strategy with potential clinical applicability